Shares of CNS Pharmaceuticals, a developer of treatments for brain cancer, surged more than 22% at the opening of trading on Monday. This follows a roughly 23% drop on Friday, June 14, when the company announced an agreement with private investors to sell $1.37 million worth of shares. Details On…